Osteopenia and osteoporosis describe reduced bone strength and an increased risk of fractures. Sarcoidosis, inactivity, nutritional factors and corticosteroid treatment can all influence risk. A clinician may review calcium and vitamin D balance, exercise, fall prevention and bone-density results. Individual treatment depends on fracture risk and other health conditions.
Bone health problems in sarcoidosis
Sarcoidosis directly affects bone in only a minority of patients. Nevertheless, bone health should be considered in the treatment of all patients with sarcoidosis. Deficiency of vitamin D, an important contributor to bone health, is associated with the occurrence of autoimmune diseases. Studies have shown that patients with sarcoidosis often have low levels of vitamin D-25 but may have normal or elevated levels of vitamin D-1,25.
In addition, granuloma formation is associated with failure of the innate immune system, which might be related to vitamin D deficiency, although this relationship has not been fully characterized. Furthermore, many patients with sarcoidosis are treated with corticosteroids, which are known to cause osteoporosis. Bone health in sarcoidosis can therefore be affected in several ways: direct involvement by granulomas, vitamin D deficiency, or corticosteroid therapy.
Less commonly, osseous lesions can infiltrate bone and cause bone resorption and bone loss. Such involvement has been reported in about 13% of patients with sarcoidosis. This estimate relies largely on case reports and, to the authors’ knowledge, has not been assessed in epidemiological studies.
Although the disease rarely affects the skeleton directly, bone health is important to consider for several reasons. First, adequate vitamin D makes an important contribution to bone health, and vitamin D deficiency is associated with autoimmune diseases. Studies have shown that patients with sarcoidosis have elevated levels of 1,25 (OH)2D (calcitriol), the active form of the vitamin.
Granuloma formation is attributed to a deficiency of innate immunity that fails to overcome mycobacterial infection. This deficiency is partly related to vitamin D.
Second, many patients with sarcoidosis are treated with corticosteroids, which cause bone loss.
Bone disease in sarcoidosis: osseous sarcoidosis and sarcoid arthritis
When sarcoid lesions are present in bone, the disease is usually systemic and progressive. Both the axial and appendicular parts of the skeleton can be affected in osseous sarcoidosis, with the hands and feet most often showing signs and symptoms. These signs and symptoms may include tenderness, swelling, stiffness, deformity, and redness near the site of bone involvement and/or associated joints. Case reports have also noted that some patients experience pain. For example, back pain may be the main symptom of granulomatous infiltration of the vertebrae.
Osseous sarcoidosis is generally detected using imaging techniques, including standard radiography, MRI, and CT. Lytic and sclerotic lesions have been observed in cases of vertebral sarcoidosis. Although most patients with sarcoidosis have evidence of thoracic parenchymal sarcoidosis on chest imaging, normal chest radiographs have also been obtained in patients with vertebral involvement. The sensitivity of MRI may make it the preferred modality for diagnosing osseous sarcoidosis, particularly when sacroiliitis is in the differential diagnosis. MRI has proved useful in identifying appropriate sites for bone biopsy.
However, lesions detected by MRI are not specific to sarcoidosis, and other diagnoses, such as malignancy and tuberculosis, must be excluded...
Vitamin D in sarcoidosis
The role of vitamin D in bone health is well established. It has a regulatory role in calcium and skeletal homeostasis and ensures intestinal calcium absorption. Vitamin D also acts in the immune system by supporting innate immunity and the destruction of foreign antigens. Recently appreciated roles of vitamin D include negative regulation of angiogenesis and promotion of cell differentiation.
Vitamin D deficiency can cause symptomatic osteomalacia, including pain, fatigue, and weakness. An estimated 36% of people in the United States have insufficient vitamin D levels. Although there is no standard definition of vitamin D deficiency, some reports suggest that levels of the inactive form, Vit D-25, below 25 ng/mL indicate deficiency.
The inactive form of vitamin D is the end product of the metabolism of synthetic vitamin D 2 and vitamin D 3, which is obtained from food or produced by the skin in response to UV light. In this inactive form, vitamin D-25 is the main circulating form of the vitamin and the form measured to assess the adequacy of vitamin D intake.
...Researchers found that 49% of patients had vitamin D-25 levels below 10 ng/mL, indicating severe vitamin deficiency. Furthermore, only one patient had an adequate serum vitamin D-25 level. Although most patients were deficient in vitamin D-25, 71% had normal values of the active form, vitamin D-1,25. Thus, patients with sarcoidosis typically have normal levels of active, but not inactive, vitamin D.
...One explanation for vitamin D-25 levels in patients with sarcoidosis is that calcium homeostasis may be altered and hypercalcemia may be present. It has long been known that sarcoidosis granulomas can autonomously increase the conversion of vitamin D-25 to vitamin D-1,25 and that hypercalcemia is associated with high vitamin D-1,25 levels. Vitamin D-1,25 is released by granulomas, and the vitamin D-1,25 level is positively correlated with disease activity.
Vitamin D-1,25 is released by granulomas, and the vitamin D-1,25 level is positively correlated with disease activity.
The conversion of vitamin D-25 to vitamin D-1,25 normally occurs in the cells of the proximal renal tubules. Vit D-1,25 is the active form of vitamin D and maintains calcium homeostasis and the balance between serum calcium and parathyroid hormone (PTH). PTH is released by the parathyroid glands in response to a decrease in circulating serum calcium. Measuring serum PTH in patients with sarcoidosis can distinguish causes of hypercalcemia, including primary hyperparathyroidism, sarcoidosis and other granulomatous diseases, and malignancies. Elevated serum PTH together with high calcium levels diagnoses primary hyperparathyroidism.
...High levels of vitamin D-1,25 have been found within granulomas. Specifically, IFN-γ, which regulates production of the enzyme 1α-hydroxylase that catalyzes conversion of vitamin D from its inactive to its active form, is produced locally at sites of granulomatous inflammation [27]. Macrophages that make up sarcoid granulomas have also been reported to produce vitamin D-1,25. Furthermore, tumor necrosis factor (TNF)-α and IFN-γ, which are present at inflammatory sites, can increase vitamin D-1,25 production.
Other cytokines, such as IFN-α, are also produced by dendritic cells at sites of inflammation. Conversely, vitamin D reduces IFN-α expression, which may help reduce inflammatory responses in patients with autoimmune diseases and in healthy individuals.
***
Bone health in sarcoidosis: managing disease- and steroid-induced osteoporosis
Given the effects of sarcoidosis on calcium and vitamin D metabolism, it is not surprising that bone mineral density (BMD) in patients with sarcoidosis may also be altered by the disease. In particular, untreated patients with sarcoidosis typically have low BMD.
Bone health in patients with sarcoidosis is complicated by the use of corticosteroids to treat active disease, which can cause increased bone resorption, reduced bone formation, and a net loss of bone mass in response to corticosteroid use.
...In patients who remain on corticosteroids for a long time, osteoporosis develops in up to 70% of cases, resulting in significant pain and disability.
Bone loss begins within the first 3 months of corticosteroid therapy but progressively decreases over time. Over time, accelerated bone loss and a corresponding tendency toward vertebral and nonvertebral fractures occur, even with low levels of corticosteroid use.
***
Proposed algorithm for maintaining bone health in sarcoidosis
...The first step is to ensure that a patient with hypercalcemia is not taking vitamin D or calcium supplements. In general, corticosteroid-based regimens are considered the standard of care for sarcoidosis. A baseline BMD measurement is therefore particularly valuable when obtained before treatment begins. Calcium and/or vitamin D supplements should be considered cautiously in patients with hypercalcemia, hypercalciuria, high PTH levels, and kidney stones.
Corticosteroids are the most reliable and rapid treatment for sarcoidosis and also correct hypercalcemia at relatively low doses. For some patients, methylprednisolone has been chosen over other corticosteroid preparations because of studies showing that steroid resistance is mediated by TLRs in patients with SLE...
Hydroxychloroquine is also used to treat patients with sarcoidosis, particularly those who may require long-term therapy. Other second-line medicines, including methotrexate and azathioprine, and third-line medicines such as anti-TNF agents are often used in patients with chronic sarcoidosis whose disease cannot be controlled with hydroxychloroquine and low-dose corticosteroids. It is important to note that anti-TNF agents have been used to treat patients with refractory sarcoidosis, with varying success...
In addition to their role in treating underlying sarcoidosis, anti-TNF agents may be useful in treating hypercalcemia and improving bone strength. Anti-TNF therapy improves bone density in rheumatoid arthritis, but whether such therapy improves bone density in patients with sarcoidosis and osteoporosis/osteopenia has not been directly evaluated. However, reports have emerged of TNF inhibitors reducing calcium levels in patients with sarcoidosis.
In sarcoidosis, studies have shown that bisphosphonates can successfully prevent osteoporosis in patients treated with corticosteroids.
Conclusion
Optimal therapies for sarcoidosis with osteoporosis, vitamin D deficiency, and abnormal calcium metabolism have not been defined because of a lack of clinical trials. Treatment should be individualized to support bone health in patients with osteopenia/osteoporosis, prevent fracture risk, and maintain normal vitamin D and calcium homeostasis.
Excerpts from the source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311464/